For research use only
| Cat No. | ABC-TC0024 |
| Product Type | Human Salivary Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Submaxillary Salivary Gland |
| Disease | Cancer |
| Product Code | A 253; A253 |
A253: Tumorigenic human salivary gland carcinoma cell line. Epithelial, adherent, near-triploid with 6+ markers.
A253 is a human salivary gland carcinoma cell line originally derived from a tumor of the submandibular gland of a 54-year-old Caucasian male. These adherent epithelial cells display a flat, cobblestone morphology and form confluent monolayers in culture. The cell line demonstrates stable growth and expresses characteristic epithelial markers, including cytokeratins. Chromosomal analysis reveals a near-diploid karyotype with chromosomal abnormalities typical of carcinoma cells. A253 cells exhibit intact epithelial junctions and are positive for EGFR, harboring TP53 mutations while retaining wild-type HRAS and NRAS. These properties make A253 a valuable in vitro model for studying the cellular biology and molecular mechanisms of salivary gland carcinoma.
| Product Code | A 253; A253 |
| Species | Human |
| Cat.No | ABC-TC0024 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Submaxillary Salivary Gland |
| Disease | Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Salivary Cancer Cell Lines |
A253 cells enable cancer research on tumor growth, metastasis, and drug resistance mechanisms while supporting HNSCC drug development through efficacy/toxicity testing. They facilitate cell signaling studies of growth/differentiation/apoptosis pathways and epigenetic research into cancer progression. These cells serve as in vitro models for assessing drug/chemical/radiation effects and studying cellular processes. Additionally, A253 cells advance new HNSCC therapies (e.g., anti-EGFR immunotoxins), evaluate drug resistance mechanisms, investigate cell communication (muscarinic/β-adrenergic receptors), probe tumor metabolism for therapeutic targeting, study laminin-mediated adhesion/differentiation, evaluate sonodynamic therapy’s apoptotic efficacy, and analyze calcium mobilization mechanisms.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
